Inhibrx Inc (INBX)
34.66
-0.04
(-0.12%)
USD |
NASDAQ |
May 10, 10:58
Inhibrx Debt to Equity Ratio: 4.758 for Dec. 31, 2023
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
Date | Value |
---|---|
December 31, 2023 | 4.758 |
September 30, 2023 | 1.587 |
June 30, 2023 | -8.241 |
March 31, 2023 | 13.43 |
December 31, 2022 | 3.480 |
September 30, 2022 | -4.874 |
June 30, 2022 | -34.50 |
March 31, 2022 | 3.990 |
December 31, 2021 | 1.345 |
September 30, 2021 | 2.485 |
Date | Value |
---|---|
June 30, 2021 | 1.572 |
March 31, 2021 | 0.4859 |
December 31, 2020 | 0.3875 |
September 30, 2020 | 0.1071 |
June 30, 2020 | -0.0974 |
March 31, 2020 | |
December 31, 2019 | -0.3626 |
September 30, 2019 | |
June 30, 2019 | -0.542 |
March 31, 2019 | -0.1335 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
-34.50
Minimum
Jun 2022
13.43
Maximum
Mar 2023
-0.8815
Average
0.4859
Median
Mar 2021
Debt to Equity Ratio Benchmarks
Axonics Inc | 0.00 |
NovaBay Pharmaceuticals Inc | 0.3431 |
Palatin Technologies Inc | 0.00 |
iBio Inc | -- |
Theriva Biologics Inc | -- |
Debt to Equity Ratio Related Metrics
Total Assets (Quarterly) | 307.89M |
Total Liabilities (Quarterly) | 264.39M |
Shareholders Equity (Quarterly) | 43.50M |
Current Ratio | 5.245 |
Net Debt Paydown Yield | -0.40% |